scholarly journals A phase 1 study of buparlisib and bevacizumab in patients with metastatic renal cell carcinoma progressing on vascular endothelial growth factor-targeted therapies

Cancer ◽  
2016 ◽  
Vol 122 (15) ◽  
pp. 2389-2398 ◽  
Author(s):  
Rana R. McKay ◽  
Guillermo De Velasco ◽  
Lillian Werner ◽  
Joaquim Bellmunt ◽  
Lauren Harshman ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
Cell Carcinoma ◽  
Targeted Therapies ◽  
Renal Cell ◽  
Phase 1 ◽  
Vascular Endothelial ◽  
Phase 1 Study ◽  
Endothelial Growth Factor

Treatment sequencing strategies in metastatic renal cell carcinoma: A critical interpretation of available data

2020 ◽  
Vol 4 (3) ◽  
pp. 153-164
Author(s):  
Mimma Rizzo ◽  
Matteo Santoni ◽  
Camillo Porta
Keyword(s):  
Renal Cell Carcinoma ◽  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
Cell Carcinoma ◽  
Metastatic Renal Cell Carcinoma ◽  
Targeted Therapies ◽  
Renal Cell ◽  
World Population ◽  
Vascular Endothelial ◽  
Endothelial Growth Factor

Therapeutic sequencing strategies for metastatic renal cell carcinoma have evolved significantly over time. For about 10 years, vascular endothelial growth factor receptor-targeted therapies and mammalian target of rapamycin inhibitors have been the standard of care. About 5 years ago an immunocheckpoint inhibitor, nivolumab, has opened new therapeutic perspectives. Recent clinical studies have confirmed the biological rationale of combining two immunocheckpoint inhibitors or vascular endothelial growth factor-targeted therapies plus immunocheckpoint inhibitors, demonstrating an improvement in clinical outcomes. We are still unable to recognize immunocheckpoint inhibitors responder patients from vascular endothelial growth factor-targeted therapies responder patients and, therefore, to quantify in a certain patient the benefits/harms ratio of upfront combination over sequence therapy in a certain patient. However, the metastatic renal cell carcinoma records of high-volume cancer centers could reveal the effectiveness and tolerability of combined treatments and indicate the potentially predictive factors and the management strategies in the real-world population.

Sign in / Sign up

Export Citation Format

Share Document